NASDAQ$VNDA
Vanda Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported a net loss with a revenue increase compared to the previous year.
Vanda Pharmaceuticals reported a net loss of $4.5 million for Q2 2024, compared to a net income of $1.5 million in Q2 2023. However, total revenues increased by 10% to $50.5 million compared to Q2 2023.
- Total revenues for Q2 2024 were $50.5 million, a 10% increase compared to Q2 2023.
- Fanapt® net product sales were $23.2 million, a 4% decrease compared to Q2 2023.
- HETLIOZ® net product sales were $18.7 million, a 15% decrease compared to Q2 2023 due to generic competition.
- PONVORY® net product sales were $8.6 million in the second quarter of 2024.
Headline financials
Revenue & EPS history
Vanda · Revenue · Quarterly
$50.5M
Revenue by segment
Vanda · $38.8M total across 2 segments · Q3 2023
- Fanapt$21.3M-11.2%54.9%
- HETLIOZ$17.5M-57.6%45.1%
Forward guidance
Vanda reinstates financial guidance and expects to achieve the following financial objectives in 2024:
Tailwinds
- Total revenues are expected to be between $180 to $210 million.
- Year-end cash is expected to be between $360 to $390 million.
- Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024
- PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024
- Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024
Headwinds
- Net loss was $4.5 million in the second quarter of 2024
- HETLIOZ® net product sales decreased 15% due to generic competition
- The FDA provided a preliminary notice that deficiencies preclude discussion of labeling for Tradipitant
- Cash decreased to $387.7 million
- Fanapt net product sales decreased 4%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.7%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+24.8%
Q2 2019
Best reaction
-23.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.5% | -13.8% | -19.1% | |
| Q4 2025 | -17.6% | -16.6% | +18.6% | |
| Q3 2025 | -0.9% | -1.4% | +21.4% | |
| Q1 2025 | -3.9% | -9.1% | +5.3% | |
| Q4 2024 | -6.0% | -3.2% | +6.0% | |
| Q3 2024 | +4.8% | +11.5% | +1.0% | |
| Q2 2024 | -3.4% | -9.1% | -9.4% | |
| Q1 2024 | -8.6% | -7.8% | +11.7% | |
| Q4 2023 | +9.1% | +16.1% | +3.8% | |
| Q3 2023 | -23.7% | -23.0% | -15.1% | |
| Q2 2023 | -8.8% | -13.4% | -14.3% | |
| Q1 2023 | +7.0% | +7.9% | -5.6% | |
| Q4 2022 | -4.6% | -4.5% | -18.0% | |
| Q3 2022 | -4.8% | -0.2% | +2.5% | |
| Q2 2022 | -1.2% | +0.9% | -0.5% | |
| Q1 2022 | -6.2% | -0.1% | -0.8% | |
| Q4 2021 | -5.0% | -15.2% | -14.5% | |
| Q3 2021 | -11.8% | -11.9% | -21.2% | |
| Q2 2021 | -7.4% | -12.4% | -10.5% | |
| Q1 2021 | +5.1% | +7.2% | +8.6% | |
| Q4 2020 | +20.5% | +17.6% | +15.5% | |
| Q3 2020 | +3.8% | +3.5% | +17.2% | |
| Q2 2020 | +6.2% | +10.2% | -5.3% | |
| Q1 2020 | -4.4% | +0.4% | -2.5% | |
| Q4 2019 | -3.7% | -6.2% | -20.5% | |
| Q3 2019 | +7.6% | +10.2% | +29.4% | |
| Q2 2019 | +24.8% | +21.2% | +11.4% | |
| Q1 2019 | -3.1% | +1.3% | -9.9% | |
| Q4 2018 | +9.3% | +14.7% | -0.7% | |
| Q3 2018 | +16.7% | +12.5% | +37.2% | |
| Q2 2018 | +4.1% | +2.4% | -7.3% | |
| Q1 2018 | +10.6% | +11.0% | +25.1% | |
| Q4 2017 | +6.6% | +7.9% | +4.7% | |
| Q3 2017 | -16.8% | -16.5% | -11.7% | |
| Q2 2017 | +7.1% | +3.5% | +11.3% | |
| Q1 2017 | -0.3% | -3.3% | -8.0% | |
| Q4 2016 | -0.7% | +2.7% | -1.7% | |
| Q3 2016 | -8.4% | -2.3% | +4.7% | |
| Q2 2016 | +2.7% | +8.5% | +36.9% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -0.6% | — | — | |
| Q3 2015 | -9.5% | — | — | |
| Q2 2015 | +8.3% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | +8.3% | — | — | |
| Q2 2014 | -11.3% | — | — | |
| Q1 2014 | -20.2% | — | — | |
| Q4 2013 | +7.2% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +4.0% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -6.2% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +6.5% | — | — | |
| Q4 2009 | +6.5% | — | — | |
| Q3 2011 | -2.2% | — | — | |
| Q3 2010 | -2.2% | — | — | |
| Q4 2010 | -10.9% | — | — | |
| Q2 2011 | -10.9% | — | — | |
| Q2 2010 | -10.9% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q1 2010 | +7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro